Edoxudine is a deoxythymidine analog used to treat herpetic keratitis. Edoxudine is a deoxythymidine analog with activity against herpes simplex virus.
- Mechanism
- Curator reviewed · 2 references
Edoxudine is a potent inhibitor of the replication of herpes simplex virus type 1 and 2. For the activation of this drug, the action of viral thymidine kinase is required to phosphorylate this molecule in order to form the 5'-monophosphate derivative. Then, it is needed to be further phosphorylated by cellular enzymes until the formation of the 5'-triphosphate derivative which is a competitive inhibitor of the viral-coded DNA polymerase. The advantage of edoxudine is that it is highly selective, this characteristic can be seen by its preferential phosphorylation in herpes-infected cells and its preferential incorporation into viral DNA.
- Primary indication
- Edoxudine was used in Europe, in the form of a topical antiviral, for the treatment of human herpes keratitis.Curator reviewed
- Formula / weight
- C11H16N2O5 · 256.258 g/mol (avg)
- First approval
- Canada, 1992
- Code names
- ORF-15817 · RWJ-15817
Resolves to
XACKNLSZYYIACO-DJLDLDEBSA-NSMILESCCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=OWhat you can answer from here — as of March 06, 2025
Which drugs share a target with Edoxudine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account